Gland Pharma Q3 Results: Gland Pharma, on Wednesday, posted a sharp 27.74% increase in its consolidated net profit for the third quarter of the ongoing fiscal year at ₹261.48 crores. The company had posted a net profit of ₹204.69 crore in the same period last year.
Its revenue from operations during the quarter under review rose 22.49% year-on-year (YoY) to ₹1695.36 crore, according to the exchange filing shared by the company.
On the operating front, its EBITDA came in 21% YoY higher at ₹434.9 crore from ₹360 crore a year ago. Margins remained steady at 26% YoY but rose from 21% in the quarter ended September 2025.
In Q3 FY26, Gland Pharma recorded an exceptional item of ₹24.34 crore, reflecting the impact of the new Labor Code on gratuity and leave-related employee benefit liabilities for the quarter ended December 31, 2025.
Gland Pharma Q3: Other details
USA, Gland Pharma’s biggest market, saw a 19% YoY growth to ₹868.5 crore, while European and Indian markets recorded a robust 54% and 32% rise in the said period to ₹407.1 crore and ₹74.4 crore, respectively.
The company’s total R&D expenses were ₹65 crore in Q3 FY26, representing 5.4% of revenue versus ₹43.7 crore, representing 4.3% of revenue, in Q3 FY25. The increase in R&D is on account of complex product development and the number of filings.
The company said it launched nine molecules in the USA this quarter. Additionally, two new launches were made in other regulated markets of Europe, Canada, Australia and New Zealand.
Gland Pharma also stated that it filed nine ANDAs in Q3, and four were approved, contributing to a cumulative total of 384 ANDA filings in the US, with 331 approved and 53 pending.
There were three new filings in Q3 FY26, contributing to a cumulative total of 134 filings in the other regulated markets.
Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong Q3 FY26 performance, driven by robust year-on-year revenue growth of 22% and healthy adj. EBITDA margin of 26% reflects the disciplined execution across our businesses. We remain confident in sustaining this momentum as new product launches, CDMO contract ramp‑ups, and operational efficiencies continue to strengthen our trajectory.”
Disclaimer: This story is for educational purposes only. We advise investors to consult with certified experts before making any investment decisions.
